
jul pm et
summari compani lead wholesal distributor pharmaceut medical-surg
suppli relat product broad rang health care custom
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul stock trade
quarter hit record-high
ebitda ex-interest renew key contract
largest custom june
improv ebitda occur
challeng cordi medic product
busi exam glove distribut
despit increas ebitda quarter
lower fy jun ep guidanc
previou
larg driven increas estim tax
rate fiscal year well inventori
write-down cordi unit like
produc surpris loss note
cordi grow top line current
issu may fixabl time also given
rest medic segment grow
estim cordi less total
revenu view littl impact
long-term valu firm
expect fy ep drop
fy follow fy see
record-high fda drug approv
potenti catalyst drive growth
support guidanc largest
store retail prescript
volum growth cy
fear
enter health care distribut help
drive share year
end june believ barrier entri
industri high howev cnbc
report april would shelv
distribut effort due difficulti win
sticki hospit custom
complex infrastructur around
acquisit pillpack mail-ord retail
pharmaci neutral view
pharmaci custom drug
distributor competitor
risk view includ unresolv cordi
litig cost price pressur
prescript drug renew effort
compet directli distributor loss
major custom
target price impli ev/ebitda
multipl fy ebitda discount
five-year averag multipl
compar reflect
transpar issu medic segment
multipl also repres
discount current comp averag
estim fy free cash flow yield
recent market cap ex-cash
risk assess reflect benefit
diversifi product servic think
strong long-term growth prospect drug health
care suppli distributor develop popul age
expand middl class around world gain
access health care view barrier entri
industri high also see recent stretch
distribut contract negoti could less favor
result vertic integr medic devic
manufactur also present greater oper
litig risk view
aug ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview inc third largest health care distribut compani
 connect manufactur pharmaceut medic suppli broad rang
downstream custom includ pharmaci hospit outpati surgeri center clinic
laboratori oper two segment revenu oper profit
fy jun medic revenu oper profit
segment distribut brand gener drug specialti pharmaceut
oncolog infus medic medic segment manufactur distribut broad rang
product medic glove endovascular stent segment util nation network
distribut center segment focus medic oper
 canada europ asia growth oper margin gener higher medic segment
fy saw medic y/i oper profit growth oper margin versu y/i growth
margin
largest custom optumrx pharmaci account fy
revenu respect five largest custom account revenu distribut
agreement extend june optumrx recent extend fy
market profil accord data iqvia hda research foundat pharmaceut sale
reach cy cy pharmaceut sale move
distribut compani cy remaind move directli manufactur
downstream custom within industri sale specialti drug grow faster
tradit drug specialti grew cy tradit contract result
sale mix shift traditional/specialti cy cy
increas access health insur especi middl class expand age popul
posit driver health care distribut drug price inflat deflat one
critic factor profit return wareh logist inventori data servic larg
distribut contract typic pay distributor negoti percentag purchas order amount
price often negoti manufactur downstream custom rise drug price
therefor lead larger whole dollar servic fee inflat also help distributor tradit resal
arrang purchas bulk inventori manufactur resel downstream
custom gain spread increas lower-cost exist inventori sold new higher price
big three pharmaceut distributor
pursu consolid strategi recent year lead increas combin market share
cy addit gener drug sourc joint ventur larg retail
pharmaci becom standard began collabor jv improv
bargain power gener manufactur set similar jv walgreen
respect
increas bargain power manufactur like factor gener price deflat trend
last sever year contribut pharmaceut sale growth slow
respect slower growth tradit drug busi led
distributor seek higher growth margin segment specialti pharmaceut
corpor strategi differenti big three pharma distributor due
greater exposur medic suppli manufactur distribut medic segment
focus grow busi well specialti pharma busi captur higher growth
margin creat one-stop-shop healthcar provid
recent activ significantli expand medic segment includ octob
acquisit cordi global manufactur distributor cardiolog devic june
acquisit patient recoveri busi manufactur distribut
medic product categori may patient recoveri acquisit perform accord
plan cordi signific drag earn growth due signific inventori write-down
mount litig cost
competit landscap oper highli competit environ particularli larg
rival segment medic suppli busi one top
price product offer value-ad servic program deliveri time credit term primari
competit factor industri larg multi-year contract consolid amongst downstream
custom major impact distributor earn case lost
signific pharmaci busi merger safeway albertson also medic
suppli distribut agreement kaiser permanent health network incumb
financi trend fy achiev five-year compound-annual-growth-rate revenu normal
ep aid stock buyback fy ebitda margin fy
line averag fy view balanc sheet strong cash
ebitda/net interest expens net debt/ebitda march leverag ratio
like improv materi full year patient recoveri acquisit reflect trail ebitda
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued
neutral sinc may technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
pressur fee distributor receiv
supplier
contributor margin expans
cost control divestitur
under-perform unit profit
stock benefit acquisit
april health
distributor decreas vs
declin composit
sub-industri index fell
versu gain
fundament outlook health care
distributor sub-industri next
month neutral outlook base mainli
favor demand trend see drug
suppli segment gener compris
busi three larg
drug distributor make bulk
market-cap weight sub-industri index
partial off-set drug reimburs drug
price cost pressur expect
distributor benefit new gener
result patent expir mani
large-sel brand drug view
gener import drug distributor
carri wider margin brand
product howev note drug price inflat
like continu moder
restrict gross profit dollar growth
acquisit strateg partner
sector also increas
cardin
drug-sourc contract
caremark partnership support
improv purchas cost greater drug
purchas scale support improv gener
longer term expect larg
distributor realiz high-single-digit
annual ep gain benefit gener drug
penetr age popul drug price
inflat addit see near term
benefit increas american
cover health insur
afford act make
pharmaceut afford note
recent repeal individu mandat
result fewer live cover
next year also see distributor top
line pressur next year
patent loss sever blockbust drug
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
commun educ prevent address opiod crisi tax plan /j
et cfra keep hold opinion share cardin
keep target price price-to-earnings fy
jun ep estim averag see
valuat hurt unfavor drug price despit medic segment strength
mar-q ep vs estim lower
expect tax pharmaceut distribut hurt gener drug price
pressur partial off-set improv purchas see jun-q comparison
eas lap custom loss fy medic result benefit
improv product mix increas distribut servic /j agnes
et cfra maintain hold opinion share cardin
inc cut target price-to-earnings
averag fy jun ep estim
cut fy ep estim
agre acquir patient recoveri busi
billion cash view deal favor diversifi
busi expand complementari medic product offer
expect fy ep accret reduc fy fy
outlook reflect greater expect deflationari gener drug price
et capit iq keep hold opinion share
inc keep target price
price-to-earnings averag fy jun
ep estim see valuat ep restrict
less favor drug price despit strength specialti medic
segment cut fy ep estim dec-q ep
vs estim margin narrow less
expect deflationari gener drug price loss larg custom
mostli off-set improv purchas accret acquisit
analyst research note compani news
style text-align justifi target impli
ev/ebitda multipl ebitda discount five-year
averag multipl competitor reflect issu
medic segment keep jun ep estim lower
ep estim view record-high fda drug approv
potenti driver ep growth support guidanc
cah largest custom health corpor
store retail prescript volum growth think recent
sell-off relat may exagger cnbc
report april would shelv health care distribut effort
due difficulti win sticki hospit custom complex
infrastructur regul drug amzn subsequ june
acquisit mail-ord retail pharmaci neutral view
pharmaci custom drug distributor competitor /colin
et cfra keep hold opinion share cardin inc
lower target price-to-earnings near
low end rang fy jun ep estim
see valuat hurt weak medic segment organ trend
unfavor drug price inflat environ cut fy ep estim
mar-q adjust ep vs
estim neg tax impact weaker cordi result revenu
growth line expect pharmaceut segment sale
slightli expect growth exist custom
specialti drug off-set recent loss prime therapeut
contract pharmaceut margin continu pressur low inflat
recent acquisit weaker expect continu challeng
cardiolog endovascular suppli busi cordi see
continu fy /joseph agnes
rais target price-to-earnings
near low end rang fy jun ep estim
think discount warrant given low drug price
inflat despit benefit see recent acquisit strength
medic specialti busi increas fy ep estim
see tax reform increas ep fy
fy dec-q ep vs estim
result benefit strong specialti demand improv purchas /joseph
lower target price-to-earnings
near low end rang fy jun ep estim
think discount warrant given low drug price
inflat despit benefit see recent acquisit strength
medic specialti busi decreas fy ep estim
sep-q ep vs estim
result hurt loss mail order custom may less
favor price despit strong specialti demand improv purchas
lower target price price-to-earnings
cah averag fy jun ep estim
believ discount warrant given unfavor
drug price trend set fy ep estim jun-q adjust
ep vs estim due lower expect
tax see fy ep hurt cost relat launch new
program pharmaceut segment drive custom growth local
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
